Mainz Biomed N.V. Ordinary Shares - MYNZ STOCK NEWS

Welcome to our dedicated page for Mainz Biomed N.V. Ordinary Shares news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed N.V. Ordinary Shares stock.

Mainz Biomed N.V. (symbol: MYNZ) is a pioneering company in the field of molecular genetic diagnostics, dedicated to providing patient-friendly testing solutions for life-threatening conditions. With a mission to improve early detection rates and thereby save lives through science, Mainz Biomed develops market-ready products that are both accurate and easy to use.

One of their key innovations is ColoAlert®, a non-invasive, at-home screening test for colorectal cancer (CRC). Utilizing real-time Polymerase Chain Reaction (PCR) to detect molecular-genetic biomarkers in stool samples, ColoAlert® offers high sensitivity and specificity. This test is available in select European countries and is poised for FDA approval in the United States through the ongoing 'ReconAAsense' clinical trial.

Mainz Biomed aims to expand its market reach by fostering partnerships with laboratories and healthcare providers. The company is also committed to advancing the early detection of other cancers, including pancreatic cancer, through products like PancAlert, which is currently in early stages of development.

Recently, Mainz Biomed showcased ColoAlert® at the UDH Congress, emphasizing its role in enhancing comprehensive health strategies. The company reported a 69% year-over-year revenue increase for ColoAlert® and maintained a stable financial condition with a $7.1 million cash balance at year-end.

In collaboration with healthcare professionals, Mainz Biomed continues to contribute to scientific research and knowledge exchange. This commitment was highlighted by their latest clinical studies, ColoFuture and eAArly DETECT, which demonstrated extraordinary statistical significance in CRC and advanced adenoma detection.

For more details, visit Mainz Biomed's official website at www.mainzbiomed.com.

11/16/2023 08:01 AM

News

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) reported a 102% increase in ColoAlert® revenue for the nine months ended September 30, 2023. The company also achieved groundbreaking clinical trial results for ColoFuture study, expanded its network of international commercial partners, and continued preparations for ReconAAsense clinical study. Financially, the company experienced a growth in revenue but an increase in operating loss due to higher sales and marketing and R&D costs.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.96%

Tags

11/15/2023 09:01 AM

News

Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering

Rhea-AI Summary

Mainz Biomed N.V. (Nasdaq: MYNZ) announced the closing of a $5.0 million registered direct offering with institutional investors to purchase ordinary shares and warrants. The offering was made pursuant to an effective shelf registration statement on Form F-3 declared effective by the SEC. Titan Partners Group, a division of American Capital Partners, acted as the sole placement agent for the offering.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.82%

Tags

11/13/2023 09:00 AM

News

Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering

Rhea-AI Summary

Mainz Biomed N.V. (MYNZ) Announces $5.0 Million Registered Direct Offering to Institutional Investors for Molecular Genetics Diagnostic Development

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-46.43%

Tags

11/09/2023 08:01 AM

News

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

Rhea-AI Summary

Mainz Biomed NV (NASDAQ:MYNZ) announced a strategic partnership with Liquid Biosciences to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing. The collaboration aims to extend the use of EMERGE to analyze the Company’s ColoFuture study, integrate novel gene expression biomarkers into ColoAlert®, and advance a self-administered CRC screening tool. Liquid Biosciences is widely considered a premier analytical partner to the life sciences industry, and EMERGE's key attributes include computational speed, ability to handle millions of variables, and unbiased methodology.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-17.14%

Tags

11/07/2023 08:01 AM

News

Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) announced that their VP Commercial Operations, Tarrin Khairi-Taraki, will attend MEDICA, a large medical B2B trade fair, to showcase ColoAlert®, the company's flagship product for at-home detection of colorectal cancer.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

13.45%

Tags

10/31/2023 08:01 AM

News

Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper

Rhea-AI Summary

Mainz Biomed announces positive interim results from its CRC screening campaign in partnership with Zöller-Kipper GmbH. Almost half of Zöller-Kipper's employees in Germany have participated in the screening program using ColoAlert®, Mainz Biomed's at-home CRC screening test.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.9%

Tags

10/26/2023 08:01 AM

News

Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

Rhea-AI Summary

Mainz Biomed appoints Tarrin Khairi-Taraki as Vice President of Commercial Operations, EMEA to focus on the commercialization of ColoAlert®, a at-home detection test for colorectal cancer.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.45%

Tags

10/18/2023 08:01 AM

News

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study

Rhea-AI Summary

Mainz Biomed presents groundbreaking results of its ColoFuture Study, showing enhanced effectiveness in non-invasive colorectal cancer screening.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.9%

Tags

10/11/2023 08:01 AM

News

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

Rhea-AI Summary

Mainz Biomed announces participation in UEG Week

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/05/2023 08:01 AM

News

Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit

Rhea-AI Summary

Mainz Biomed N.V. to attend JonesTrading 2023 Healthcare Summit

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.07%

Tags

FAQ

What is the current stock price of Mainz Biomed N.V. Ordinary Shares (MYNZ)?

The current stock price of Mainz Biomed N.V. Ordinary Shares (MYNZ) is $0.2271 as of November 1, 2024.

What is the market cap of Mainz Biomed N.V. Ordinary Shares (MYNZ)?

The market cap of Mainz Biomed N.V. Ordinary Shares (MYNZ) is approximately 5.8M.

What does Mainz Biomed specialize in?

Mainz Biomed specializes in developing molecular genetic diagnostic solutions for early detection of life-threatening conditions, such as colorectal and pancreatic cancers.

What is ColoAlert®?

ColoAlert® is Mainz Biomed's flagship product, a non-invasive, at-home test for colorectal cancer that uses PCR technology to detect molecular-genetic biomarkers in stool samples.

Where is ColoAlert® available?

ColoAlert® is currently available in select European countries and is undergoing FDA approval for the U.S. market.

What recent achievements has Mainz Biomed made?

Mainz Biomed recently presented significant clinical study results at the UDH Congress and reported a 69% year-over-year revenue increase for ColoAlert®.

What is the ReconAAsense trial?

The ReconAAsense trial is Mainz Biomed's FDA-registration study designed to evaluate ColoAlert® for U.S. regulatory approval.

What other products does Mainz Biomed have in development?

Apart from ColoAlert®, Mainz Biomed is developing PancAlert, an early-stage screening test for pancreatic cancer.

How does ColoAlert® differ from other CRC screening tests?

ColoAlert® offers higher accuracy and earlier detection rates compared to traditional fecal occult blood tests (FOBT), thanks to its advanced PCR-based technology.

What is Mainz Biomed’s mission?

Mainz Biomed's mission is to save lives through science by providing accurate, easy-to-use diagnostic solutions for early detection of deadly conditions.

How does Mainz Biomed contribute to the healthcare sector?

Mainz Biomed contributes through scientific research, innovative diagnostic solutions, and partnerships with healthcare professionals to improve early detection and patient care.